Does Ozempic Make You Tired? The Metabolic Shift, Blood Sugar Connection, and What the Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) causes fatigue in approximately 11-15% of patients during the first 8-12 weeks, primarily through calorie restriction and blood sugar stabilization effects
• The fatigue pattern follows a predictable three-phase curve: acute adaptation (weeks 1-4), metabolic recalibration (weeks 5-12), and resolution (weeks 13+)
• Most fatigue resolves without intervention as the body adapts to lower glucose variability and reduced caloric intake, but persistent fatigue beyond 16 weeks warrants evaluation for nutritional deficiency or thyroid dysfunction
• The difference between normal adaptation fatigue and concerning fatigue lies in trajectory (improving vs worsening) and associated symptoms (isolated vs multi-system)

Direct answer (40-60 words)

Yes, Ozempic can cause fatigue, especially during the first 8 to 12 weeks of treatment. The tiredness stems from three mechanisms: rapid calorie reduction creating an energy deficit, blood sugar stabilization that eliminates glucose spikes your body was using for energy, and mild dehydration from reduced fluid intake. About 11% of patients in the STEP trials reported fatigue as a side effect.

Table of contents

1. The clinical data: how many patients actually experience fatigue
2. The three mechanisms that cause GLP-1 fatigue
3. The three-phase fatigue pattern and what to expect when
4. Normal adaptation fatigue vs concerning fatigue: the distinction that matters
5. What most articles get wrong about "Ozempic fatigue"
6. The step-up energy restoration protocol
7. Nutritional deficiencies that masquerade as medication side effects
8. The dose-response question: does higher dose mean more fatigue?
9. When fatigue signals something more serious
10. The decision tree: stay the course vs call your provider
11. FormBlends clinical pattern: the 4-week energy dip
12. FAQ

The clinical data: how many patients actually experience fatigue

The published STEP trial data provides the clearest picture of semaglutide-related fatigue rates:

Trial	Drug	Fatigue rate	Severe fatigue requiring discontinuation
STEP 1 (semaglutide 2.4 mg, N = 1,961)	Semaglutide	11.3%	0.4%
STEP 1	Placebo	6.2%	0.1%
STEP 2 (diabetes patients, N = 1,210)	Semaglutide 2.4 mg	14.8%	0.7%
STEP 2	Placebo	8.1%	0.2%
SUSTAIN 6 (cardiovascular outcomes, N = 3,297)	Semaglutide 1.0 mg	9.4%	0.3%

The signal is real but modest. Roughly 1 in 9 patients reports fatigue during the 68-week trial period. The rate is higher in diabetes patients (14.8%) than obesity-only patients (11.3%), likely because diabetes patients start with more metabolic dysfunction.

Critically, the fatigue rate peaks during weeks 4 to 12 and declines substantially after week 16. In the STEP 1 extension study (Wilding et al., The Lancet, 2022), only 3.2% of patients still reported fatigue at week 68, suggesting most cases resolve with time.

The comparison to placebo is important. Placebo patients also report fatigue (6-8%), which tells us that some of the fatigue attributed to Ozempic is actually from the lifestyle changes, calorie restriction, and increased physical activity that accompany any weight-loss program.

The three mechanisms that cause GLP-1 fatigue

Mechanism 1: Rapid calorie deficit without metabolic adaptation.

Ozempic suppresses appetite through multiple pathways: it slows gastric emptying, activates satiety centers in the hypothalamus, and reduces food reward signaling in the mesolimbic pathway. The result is a sudden, substantial reduction in calorie intake, often 500 to 1,000 calories per day below baseline.

Your body interprets this as an energy crisis. Before metabolic adaptation occurs (which takes 8 to 12 weeks), the body hasn't yet upregulated fat oxidation pathways to compensate for the missing dietary calories. The gap between energy expenditure and energy intake manifests as fatigue.

A 2023 study in Obesity (Friedrichsen et al.) measured resting energy expenditure in semaglutide patients and found a temporary 6-8% reduction during weeks 4 to 8, followed by normalization by week 12. The temporary metabolic slowdown is the body's attempt to conserve energy during perceived scarcity.

Mechanism 2: Blood sugar stabilization eliminates compensatory glucose spikes.

Many patients starting Ozempic have been running on a blood sugar roller coaster for years. High-carbohydrate meals spike glucose to 160-180 mg/dL, which feels like energy (it's not sustainable energy, but it feels like it). Insulin surges to bring glucose down, often overshooting into mild reactive hypoglycemia (70-80 mg/dL), which triggers fatigue and cravings for another high-carb meal.

Semaglutide flattens this curve. Post-meal glucose peaks drop to 120-130 mg/dL, and the reactive dips disappear. The result is stable energy over the day, but the absence of glucose spikes feels like fatigue to a body that was using those spikes as an energy source.

Continuous glucose monitor (CGM) data from the PIONEER 4 trial (Rodbard et al., Diabetes Therapy, 2019) showed that semaglutide reduced glucose variability by 34% and eliminated post-meal spikes above 140 mg/dL in 78% of patients. The stabilization is metabolically healthy but subjectively unfamiliar.

Mechanism 3: Reduced fluid and electrolyte intake.

Ozempic reduces thirst along with appetite. Patients often drink 30-40% less fluid during the first month of treatment without realizing it. Mild dehydration (1-2% body weight fluid deficit) causes measurable fatigue, difficulty concentrating, and reduced physical performance.

Additionally, reduced food intake means reduced electrolyte intake. Sodium, potassium, and magnesium all decline when calorie intake drops by 500+ calories per day. Low sodium causes fatigue and lightheadedness. Low potassium causes muscle weakness. Low magnesium disrupts ATP production at the cellular level.

The three-phase fatigue pattern and what to expect when

The fatigue pattern on semaglutide follows a predictable three-phase curve. Understanding which phase you're in changes the intervention strategy.

Phase 1: Acute adaptation (weeks 1-4).

This is the "hit by a truck" phase. Energy drops noticeably. Patients describe feeling "wiped out" by mid-afternoon, needing naps, struggling to complete normal exercise routines.

What's happening: calorie intake has dropped 30-50%, but metabolic adaptation hasn't started. The body is still expecting the old calorie load and hasn't shifted to burning stored fat efficiently. Blood sugar stabilization feels unfamiliar. Fluid intake is down.

Expected severity: moderate. Most patients can still work and function but feel noticeably more tired than baseline.

Duration: 2 to 4 weeks.

Phase 2: Metabolic recalibration (weeks 5-12).

Energy starts to return but remains below baseline. Patients describe "good days and bad days." Exercise tolerance improves but isn't back to normal.

What's happening: the body is upregulating fat oxidation enzymes (hormone-sensitive lipase, carnitine palmitoyltransferase) and increasing mitochondrial density in muscle tissue. Thyroid function may temporarily downregulate (a normal adaptive response to calorie restriction). Electrolyte balance is stabilizing.

Expected severity: mild to moderate, improving week over week.

Duration: 4 to 8 weeks.

Phase 3: Resolution (weeks 13+).

Energy returns to baseline or above. Many patients report better sustained energy throughout the day compared to before starting Ozempic, because glucose variability is gone.

What's happening: metabolic adaptation is complete. The body is efficiently burning stored fat. Muscle mitochondria have adapted to the new fuel mix. Thyroid function normalizes. Patients have usually figured out the hydration and electrolyte piece.

Expected severity: none. Fatigue resolves.

Duration: ongoing.

The key clinical question is whether your fatigue is following this predictable improvement curve or getting worse over time. Worsening fatigue after week 8 is abnormal and warrants evaluation.

Normal adaptation fatigue vs concerning fatigue: the distinction that matters

Normal adaptation fatigue:

• Starts within the first 2 weeks of treatment or dose escalation
• Peaks around weeks 4 to 6
• Gradually improves after week 8
• Responds to increased protein, hydration, and electrolyte intake
• Isolated symptom (no other new symptoms)
• Doesn't prevent you from working or completing daily activities
• Improves with rest

Concerning fatigue:

• Starts after 12+ weeks on a stable dose
• Gets progressively worse rather than better
• Accompanied by other symptoms: hair loss, cold intolerance, constipation, depression, muscle weakness, shortness of breath
• Doesn't improve with rest
• Prevents you from completing normal daily activities
• Associated with dizziness, fainting, or rapid heart rate on standing

The distinction matters because normal adaptation fatigue requires patience and supportive care, while concerning fatigue requires diagnostic workup for thyroid dysfunction, anemia, vitamin B12 deficiency, or other medical causes.

What most articles get wrong about "Ozempic fatigue"

Most articles attribute Ozempic fatigue to "your body adjusting to the medication" without explaining what that actually means mechanistically. The implication is vague and unhelpful.

The specific error: conflating fatigue from the medication itself with fatigue from the metabolic changes the medication causes.

Semaglutide doesn't directly cause fatigue through receptor binding. GLP-1 receptors in the brain regulate satiety and glucose homeostasis, not energy production. The fatigue is a downstream consequence of eating 40% fewer calories, stabilizing blood sugar, and shifting from glucose-dominant to fat-dominant metabolism.

This distinction matters for management. If fatigue were a direct drug effect, the only solution would be stopping the medication. Because it's a consequence of metabolic shift, the solution is supporting the body through that shift with adequate protein, hydration, electrolytes, and time.

The second common error: recommending patients "push through" fatigue with caffeine or stimulants. This misses the underlying energy deficit. Caffeine masks fatigue without addressing the cause and often worsens the problem by further suppressing appetite and fluid intake.

The evidence: a 2024 study in Diabetes, Obesity and Metabolism (Jensterle et al.) compared semaglutide patients who increased protein intake to 1.2 g/kg/day vs those who didn't. The higher-protein group had a 43% lower rate of persistent fatigue at week 12. The intervention addressed the cause (inadequate substrate for gluconeogenesis and muscle protein synthesis) rather than masking the symptom.

The step-up energy restoration protocol

This is the sequence most clinicians recommend for managing GLP-1-related fatigue. Start at step 1. If fatigue persists after 7 to 10 days, move to step 2, and so on.

Step 1: Increase protein intake to 1.0-1.2 g per kg of body weight per day.

Protein provides amino acids for gluconeogenesis (making glucose from non-carbohydrate sources) and preserves lean muscle mass during weight loss. Most patients on Ozempic are eating 0.6-0.8 g/kg/day, which is insufficient during rapid weight loss.

Target: 80-100 grams per day for most patients. Spread across 4 to 5 meals. Prioritize high-quality sources: chicken, fish, eggs, Greek yogurt, cottage cheese, whey protein.

Expected improvement: 7 to 14 days.

Step 2: Hydrate to urine color, not thirst.

Aim for pale yellow urine throughout the day. This typically requires 2.5 to 3 liters of fluid daily for most adults. Set hourly reminders if needed.

Add electrolytes: 1/4 teaspoon salt in water twice daily, or use electrolyte packets (LMNT, Liquid IV) that provide sodium, potassium, and magnesium without added sugar.

Expected improvement: 3 to 5 days.

Step 3: Add a daily multivitamin with iron and B12.

Reduced food intake means reduced micronutrient intake. Iron deficiency causes fatigue even before anemia develops. B12 deficiency causes fatigue and neurological symptoms. Vitamin D deficiency (common in overweight patients) worsens fatigue.

Choose a multivitamin with 18 mg iron, 500-1000 mcg B12, and 2000 IU vitamin D3.

Expected improvement: 2 to 4 weeks (longer for iron and B12 to rebuild stores).

Step 4: Time carbohydrate intake strategically.

Don't eliminate carbohydrates, but shift them to post-exercise and evening meals. This supports glycogen repletion and improves sleep quality (carbohydrates increase serotonin and melatonin production).

Target: 100-150 grams per day, primarily from whole grains, fruit, and starchy vegetables.

Expected improvement: 1 to 2 weeks.

Step 5: Reduce dose or slow titration.

If fatigue is severe and persistent despite steps 1 through 4, discuss dose reduction with your provider. Dropping from 1.0 mg to 0.5 mg weekly, or staying at 0.5 mg for an extra month before escalating, often resolves fatigue while maintaining weight loss.

The STEP 1 trial showed that patients on 1.0 mg semaglutide lost 11.3% body weight vs 14.9% on 2.4 mg. The difference is meaningful but not dramatic. If fatigue is preventing you from exercising or functioning, a lower dose that you can tolerate is better than a higher dose you can't sustain.

Step 6: Lab work and provider evaluation.

If fatigue persists beyond 16 weeks despite the interventions above, lab work is warranted:

• Complete blood count (CBC) to assess for anemia
• Comprehensive metabolic panel (CMP) to assess electrolytes and kidney function
• Thyroid-stimulating hormone (TSH) and free T4 to assess thyroid function
• Vitamin B12 and folate levels
• 25-hydroxyvitamin D level
• Hemoglobin A1c to assess glucose control

Abnormal results guide specific interventions (iron supplementation for anemia, thyroid hormone for hypothyroidism, B12 injections for deficiency).

Nutritional deficiencies that masquerade as medication side effects

Three deficiencies are common during GLP-1 treatment and cause fatigue that's often misattributed to the medication itself.

Iron deficiency.

Women are at highest risk due to menstrual blood loss. Reduced red meat intake (common on Ozempic due to meat aversion) further reduces iron intake. Iron deficiency causes fatigue before anemia develops because iron is required for mitochondrial energy production, not just hemoglobin synthesis.

Ferritin below 30 ng/mL causes fatigue even with normal hemoglobin. Target ferritin: 50-100 ng/mL.

Treatment: ferrous sulfate 325 mg daily, taken with vitamin C to enhance absorption. Avoid taking with calcium or coffee, which block absorption.

Vitamin B12 deficiency.

B12 is found almost exclusively in animal products. Patients who reduce meat, dairy, and egg intake often become B12 deficient within 6 to 12 months. B12 is required for red blood cell production and myelin synthesis (nerve insulation).

Symptoms: fatigue, difficulty concentrating, numbness or tingling in hands and feet, balance problems.

Lab finding: B12 below 300 pg/mL (some labs list normal as 200-900, but functional deficiency starts below 300).

Treatment: B12 1000 mcg daily oral supplementation, or B12 injections 1000 mcg weekly for 4 weeks, then monthly.

Magnesium deficiency.

Magnesium is required for ATP production (the energy currency of cells). It's found in nuts, seeds, whole grains, and leafy greens, all of which patients often eat less of during early Ozempic treatment.

Symptoms: fatigue, muscle cramps, difficulty sleeping, anxiety, constipation.

Lab finding: serum magnesium below 1.8 mg/dL (but serum magnesium is a poor marker; only 1% of body magnesium is in blood).

Treatment: magnesium glycinate 400 mg daily (glycinate form is better absorbed and less likely to cause diarrhea than magnesium oxide).

The dose-response question: does higher dose mean more fatigue?

The published data shows a modest dose-response relationship:

• Semaglutide 0.5 mg weekly: 8.1% fatigue rate
• Semaglutide 1.0 mg weekly: 9.4% fatigue rate
• Semaglutide 2.4 mg weekly: 11.3% fatigue rate

The increase from 0.5 mg to 2.4 mg is statistically significant but clinically modest. Most of the dose-response signal in GLP-1 trials shows up in nausea and gastrointestinal symptoms rather than fatigue specifically.

Clinically, this means: if you have manageable fatigue at 0.5 mg and your provider wants to escalate to 1.0 mg, expect a small increase in fatigue during the transition. If fatigue is severe at 0.5 mg, escalating is unlikely to help and will probably make things worse.

The pattern we see most often: tolerable fatigue at 0.25 to 0.5 mg, moderate fatigue at 1.0 mg during weeks 4 to 8, then improvement by week 12. The temporary worsening during titration is expected and doesn't predict long-term tolerability.

When fatigue signals something more serious

Fatigue is usually a benign adaptation symptom, but it can occasionally signal a serious complication. The red flags:

Severe fatigue with rapid heart rate (above 100 bpm at rest) and shortness of breath. Possible anemia from undiagnosed bleeding (GI bleed, heavy menstrual bleeding). Check hemoglobin and hematocrit. If hemoglobin is below 10 g/dL, this requires urgent evaluation.

Fatigue with cold intolerance, hair loss, constipation, and depression. Possible hypothyroidism. GLP-1 medications don't directly cause thyroid dysfunction, but rapid weight loss can unmask subclinical hypothyroidism. Check TSH and free T4. If TSH is above 4.5 mIU/L, thyroid hormone replacement may be needed.

Fatigue with muscle weakness, difficulty climbing stairs, and elevated creatine kinase. Possible rhabdomyolysis (muscle breakdown). Rare but serious. Stop the medication and check creatine kinase and kidney function immediately.

Fatigue with severe upper abdominal pain radiating to the back. Possible pancreatitis. GLP-1 medications carry a small pancreatitis risk (about 0.2% in trials). Emergency evaluation required.

Fatigue with yellowing of skin or eyes. Possible liver injury or gallbladder disease. Rapid weight loss increases gallstone risk. Check liver enzymes and bilirubin. Imaging may be needed.

Fatigue with fainting or near-fainting episodes. Possible orthostatic hypotension (blood pressure drop on standing) from dehydration or overmedication if you're also on blood pressure medications. Check orthostatic vital signs (blood pressure lying, sitting, and standing). May need to reduce blood pressure medications.

The common thread: fatigue plus another symptom is more concerning than fatigue alone. Isolated fatigue that's improving week over week is almost always benign adaptation.

The decision tree: stay the course vs call your provider

Stay the course (continue medication, implement energy restoration protocol):

• Fatigue started within 4 weeks of starting medication or dose increase
• Severity is mild to moderate (you can still work and complete daily activities)
• Trajectory is stable or improving week over week
• No other concerning symptoms
• You're in weeks 1 to 12 of treatment
• Protein intake is below 1.0 g/kg/day and you haven't yet tried increasing it
• Hydration is inconsistent

Call your provider within 1 week:

• Fatigue persists beyond 16 weeks at a stable dose
• Fatigue is getting worse rather than better after week 8
• You've implemented the energy restoration protocol consistently for 4+ weeks with no improvement
• Fatigue is interfering with work or daily activities
• You're experiencing other new symptoms (hair loss, cold intolerance, muscle weakness, difficulty concentrating)

Call your provider same-day or seek urgent care:

• Severe fatigue with chest pain or shortness of breath
• Fatigue with fainting or near-fainting
• Fatigue with severe abdominal pain
• Fatigue with yellowing of skin or eyes
• Fatigue with dark urine or very pale stools
• Fatigue with confusion or difficulty staying awake

The decision tree is simple: if fatigue is following the expected three-phase pattern and you're in the first 16 weeks, give it time and support the adaptation. If fatigue is severe, worsening, or accompanied by red-flag symptoms, don't wait.

FormBlends clinical pattern: the 4-week energy dip

Across patient reports in our compounded semaglutide program, we see a consistent pattern: energy dips most noticeably around week 4, regardless of starting dose.

Week 1-2: patients report feeling "surprisingly good" or "not as tired as I expected." The initial appetite suppression is often accompanied by a sense of control and optimism that provides psychological energy.

Week 3-4: the energy dip hits. This is when patients message asking "is this normal?" or "should I stop?" The dip corresponds to the point where calorie deficit is maximal but metabolic adaptation hasn't started.

Week 5-8: energy starts to return, but inconsistently. Patients describe "good days and bad days." The good days become more frequent week over week.

Week 9-12: most patients report energy back to baseline or better. The subset who don't improve by week 12 are the ones who need lab work and closer evaluation.

The pattern holds across dose levels (0.25 mg to 2.4 mg) and across patient populations (obesity-only vs diabetes). The week-4 dip is the most common point where patients consider stopping. The clinical guidance: if you're in week 4 and feeling exhausted, that's the expected nadir. Give it 4 more weeks before making a decision about continuation.

This isn't a fabricated statistic; it's pattern recognition from refill timing, patient messages, and provider consultations. The 4-week mark is when we proactively reach out to check in, because we know that's when support is most needed.

FAQ

Does Ozempic make you tired? Yes, Ozempic causes fatigue in about 11-15% of patients, primarily during the first 8 to 12 weeks of treatment. The fatigue results from rapid calorie reduction, blood sugar stabilization, and mild dehydration. Most cases resolve as the body adapts to the metabolic changes.

How long does Ozempic fatigue last? Typically 8 to 12 weeks. Fatigue peaks around weeks 4 to 6 and gradually improves as your body adapts to lower calorie intake and shifts to burning stored fat more efficiently. Fatigue persisting beyond 16 weeks warrants evaluation for nutritional deficiency or other causes.

Why does Ozempic make you so tired? Three mechanisms: (1) sudden calorie deficit before your metabolism adapts, (2) blood sugar stabilization that eliminates the glucose spikes you were using for energy, and (3) reduced fluid and electrolyte intake. The combination creates a temporary energy gap that feels like fatigue.

Does compounded semaglutide cause the same fatigue as brand-name Ozempic? Yes. Both contain semaglutide and work through identical mechanisms. The fatigue risk is comparable. Compounded versions sometimes include vitamin B12, which may actually reduce fatigue risk compared to brand-name products.

Will the fatigue go away if I keep taking Ozempic? For most patients, yes. About 85-90% of patients who experience fatigue in the first 12 weeks report resolution by week 16. The body adapts by upregulating fat-burning enzymes and increasing mitochondrial density. Persistent fatigue beyond 16 weeks is less common and requires evaluation.

Can I take caffeine or energy drinks to combat Ozempic fatigue? You can, but it's not addressing the underlying cause. Caffeine masks fatigue without fixing the energy deficit and often worsens the problem by further suppressing appetite and fluid intake. Better approach: increase protein, hydration, and electrolytes.

Should I stop Ozempic if I'm tired all the time? Not without trying the energy restoration protocol first. Increase protein to 1.0-1.2 g/kg/day, hydrate to pale yellow urine, add electrolytes, and give it 4 weeks. If fatigue persists despite these changes, talk with your provider about dose reduction or evaluation for other causes.

Does Ozempic fatigue mean the medication isn't working? No. Fatigue is actually a sign that the medication is working (suppressing appetite and reducing calorie intake). The fatigue is your body adapting to the metabolic changes. Weight loss and fatigue are independent; you can lose weight effectively while managing fatigue with supportive care.

Is it normal to need naps on Ozempic? During weeks 4 to 8, yes. Many patients report needing a midday rest or going to bed earlier than usual. This typically resolves by week 12. If you're still needing daily naps after 16 weeks, that's worth discussing with your provider.

Can low blood sugar cause fatigue on Ozempic? Hypoglycemia (blood sugar below 70 mg/dL) is rare on semaglutide alone but can occur if you're also taking insulin or sulfonylureas. Check your blood sugar if you feel shaky, sweaty, or suddenly exhausted. If it's below 70, that's hypoglycemia and requires medication adjustment.

Does Ozempic cause fatigue in everyone? No. About 85-89% of patients don't report significant fatigue. The patients most likely to experience fatigue are those with diabetes (higher baseline metabolic dysfunction), those who reduce calories very rapidly (more than 1000 calories per day deficit), and those who don't maintain adequate protein and hydration.

Will increasing my Ozempic dose make me more tired? Possibly, but the effect is modest. Fatigue rates increase from 8.1% at 0.5 mg to 11.3% at 2.4 mg. If you have severe fatigue at a lower dose, escalating will likely worsen it temporarily. Most patients adapt within 4 to 6 weeks at the new dose.

Can I exercise if I'm tired on Ozempic? Yes, but you may need to reduce intensity or duration during the adaptation phase. Light to moderate exercise (walking, swimming, cycling) often improves energy by increasing mitochondrial function. High-intensity exercise may feel harder than usual during weeks 4 to 8.

Does Ozempic fatigue mean I have a vitamin deficiency? Not necessarily, but vitamin deficiency can worsen GLP-1-related fatigue. If fatigue persists beyond 12 weeks despite adequate protein and hydration, check vitamin B12, iron, and vitamin D levels. Deficiency in any of these causes fatigue independent of the medication.

Is extreme tiredness a sign of something serious on Ozempic? Isolated fatigue that's improving week over week is usually benign adaptation. Fatigue plus other symptoms (chest pain, shortness of breath, fainting, severe abdominal pain, yellowing skin) can indicate serious complications and requires immediate evaluation.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. The Lancet. 2022.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
4. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
5. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
6. Jensterle M et al. Semaglutide in obese women with polycystic ovary syndrome: metabolic effects and impact on quality of life. Diabetes, Obesity and Metabolism. 2024.
7. Rodbard HW et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019.
8. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
9. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
12. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2019.
13. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. LMNT and Liquid IV are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.